# US 2020/0269197 A1 · Membrane for blood purification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0269197 A1
- Document ID: US20200269197A1
- Status: Published application
- Kind: A1
- Application number: 16/851,432
- Filed: 2020-04-17
- Published: 2020-08-27
- Earliest claimed: 2014-02-06
- Assignees: Gambro Lundia AB
- Applicants: Gambro Lundia AB
- Inventors: Adriana BOSCHETTI-DE-FIERRO; Manuel VOIGT; Bernd KRAUSE; Markus HORNUNG; Markus STORR; Heinrich BEHR; Werner BECK; Carina ZWEIGART; Reinhold BUCK; Philipp HERBST; Joachim LOERCHER; Arnd WOCHNER
- Web page: https://patentgrep.com/patent/US20200269197A1

## CPC

- B01D 71/68: Polysulfones; Polyethersulfones
- A61M 1/1621: {Constructional aspects thereof (semi-permeable membranes for separation processes characterised by their properties B01D69/00; semi permeable membranes characterised by their material B01D71/00)}
- A61M 1/3413: {Diafiltration}
- B01D 61/243: {Dialysis}
- B01D 63/0233: {forming the bundle}
- B01D 69/081: {characterised by the fibre diameter}
- B01D 69/084: {Undulated fibres}
- B01D 69/087: {Details relating to the spinning process}
- B01D 71/381: {Polyvinylalcohol}
- B01D 71/441: {Polyvinylpyrrolidone}
- A61M 1/16: with membranes
- B01D 2252/102: Ammonia
- B01D 2258/0283: Flue gases
- B01D 2323/06: Specific viscosities of materials involved
- B01D 2323/12: Specific ratios of components used
- B01D 2325/022: Asymmetric membranes
- B01D 2325/025: Finger pores
- B01D 2325/026: Sponge structure
- B01D 2325/04: Characteristic thickness
- B01D 2325/20: Specific permeability or cut-off range
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present disclosure relates to semipermeable membranes which are suitable for blood purification, e.g. by hemodialysis, which have an increased ability to remove larger molecules while at the same time effectively retaining albumin. The membranes are characterized by a molecular retention onset (MWRO) of between 9.0 kD and 14.5 kD and a molecular weight cut-off (MWCO) of between 55 kD and 130 kD as determined by dextran sieving curves and can be prepared by industrially feasible processes excluding a treatment with salt before drying. The invention therefore also relates to a process for the production of the membranes and to their use in medical applications.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A membrane comprising i) at least one hydrophobic polymer component and ii) at least one hydrophilic polymer component, wherein the membrane has a molecular retention onset (MWRO) of between 9.0 kDa and 14.0 kDa and a molecular weight cut-off (MWCO) of between 55 kDa and 130 kDa as determined by dextran sieving before blood contact of the membrane.

### Claim 13 (depends on 12)

The membrane of claim 12, wherein the membrane is a hollow fiber membrane.

### Claim 14 (depends on 12)

The membrane of claim 12, wherein the membrane is a flat sheet fiber membrane.

### Claim 15 (depends on 12)

The membrane of claim 12, wherein the hydrophobic polymer component is poly(aryl)ethersulfone (PAES).

### Claim 16 (depends on 12)

The membrane of claim 12, wherein the hydrophilic polymer component is polyvinylpyrrolidone (PVP).

### Claim 17 (depends on 12)

The membrane of claim 12, wherein the hydrophobic polymer component is poly(aryl)ethersulfone (PAES) and the hydrophilic polymer component is polyvinylpyrrolidone (PVP), and
wherein the membrane comprises between 2.0 wt.-% to 4.0 wt.-% PVP and a balance of poly(aryl)ethersulfone adding up to 100%.

### Claim 18 (depends on 15)

The membrane of claim 15, wherein the membrane comprises a second hydrophobic polymer component.

### Claim 19 (depends on 18)

The membrane of claim 18, wherein the second hydrophobic polymer component is polyamide.

### Claim 20 (depends on 13)

The membrane of claim 13, wherein the hollow fiber membrane comprises a wall thickness from 30 μm to 49 μm.

### Claim 21 (depends on 13)

The membrane of claim 13, wherein the hollow fiber membrane comprises a wall thickness from 30 μm to 40 μm.

### Claim 22 (depends on 13)

The membrane of claim 13, wherein the hollow fiber membrane comprises an inner diameter from 170 μm to 200 μm.

### Claim 23 (depends on 13)

The membrane of claim 13, wherein the hollow fiber membrane comprises an inner diameter from 175 μm to 185 μm.

### Claim 24 (depends on 12)

The membrane of claim 12, wherein the membrane has a molecular retention onset (MWRO) of between 9.0 kDa and 12.5 kDa and a molecular weight cut-off (MWCO) of between 68 kDa and 110 kDa as determined by dextran sieving before blood contact of the membrane.

### Claim 25 (depends on 12)

The membrane of claim 12, wherein the membrane has a molecular retention onset (MWRO) of between 10.0 kDa and 12.5 kDa and a molecular weight cut-off (MWCO) of between 68 kDa and 90 kDa as determined by dextran sieving before blood contact of the membrane.

### Claim 26 (depends on 12)

The membrane of claim 12, wherein the membrane has a molecular retention onset (MWRO) of between 10.0 kDa and 12.5 kDa and a molecular weight cut-off (MWCO) of between 65 kDa and 90 kDa as determined by dextran sieving before blood contact of the membrane.

### Claim 27 (depends on 12)

The membrane of claim 12, wherein the membrane has an asymmetric finger-like structure comprising at least three layers,
wherein the first layer is a separation layer,
wherein the second layer is a sponge structure, and
wherein the third layer is a finger structure.

### Claim 28 (depends on 27)

The membrane of claim 27, wherein the first layer has a thickness of less than 0.5 μm.

### Claim 29 (depends on 27)

The membrane of claim 27, wherein the second layer has a thickness of about 1 μm to 15 μm.

### Claim 30 (depends on 27)

The membrane of claim 27, wherein the third layer has a thickness of 20 μm to 30 μm.

### Claim 31 (depends on 27)

The membrane of claim 27, wherein the membrane further comprises a fourth layer, wherein the fourth layer is an outer surface.
